NCT04073979 is a NA clinical trial of Mistral implantation in Tricuspid Valve Regurgitation, sponsored by Mitralix.

Who is sponsoring NCT04073979?

NCT04073979 is sponsored by Mitralix.

What drugs are being tested in NCT04073979?

Interventions in NCT04073979: Mistral implantation.

What condition does NCT04073979 study?

NCT04073979 studies Tricuspid Valve Regurgitation.

Is NCT04073979 still recruiting?

NCT04073979 is currently completed. Last updated 19 October 2023.

Last reviewed 2023-10-19 · How we verify

NCT04073979

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MATTERS II - Mistral Percutaneous Tricuspid Valve Repair FIM Study

Completed NA Last updated 19 October 2023

What this trial tests

NA trial testing Mistral implantation in Tricuspid Valve Regurgitation in 9 participants. Completed in 31 December 2022.

Timeline

2 April 2019

Primary endpoint
31 January 2021

31 December 2022

Quick facts

Lead sponsor	Mitralix
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	2 April 2019
Primary completion	31 January 2021
Estimated completion	31 December 2022
Sites	4 locations across Germany

Drugs / interventions tested

Mistral implantation

Conditions studied

Tricuspid Valve Regurgitation — all drugs for Tricuspid Valve Regurgitation →

Sponsor

Mitralix

Who can join

18 and older, any sex, with Tricuspid Valve Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR). The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Transcatheter tricuspid valve interventions: Current status and future perspectives.
Alperi A, Almendárez M, Álvarez R, Moris C, et al · · 2022 · cited 19× · PMID 36187002 · DOI 10.3389/fcvm.2022.994502
One-year outcomes of transcatheter tricuspid valve repair with the Mistral device.
Piayda K, Bertog S, Steffan J, Ilioska-Damköhler P, et al · · 2023 · cited 5× · PMID 36912107 · DOI 10.4244/eij-d-22-01032
Percutaneous Tricuspid Valve Repair.
Mangieri A, Sticchi A, Gohar A, Regazzoli D, et al · · 2022 · cited 3× · PMID 39076922 · DOI 10.31083/j.rcm2307220

Verify or expand the search:

Other trials of Mistral implantation

Trials testing the same drug.

NCT04071652 — MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study · NA · completed

Other recruiting trials for Tricuspid Valve Regurgitation

Currently open trials in the same condition.

NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
NCT06611579 — Clinical Study of the inQB8 TTVR System · NA · recruiting
NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
NCT06581471 — The TRICURE EU Pivotal Study · NA · recruiting
NCT07342036 — Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion · recruiting

Other Mitralix trials

Trials by the same sponsor.

NCT05767645 — Mistral Percutaneous Tricuspid Valve Durable Repair Pivotal Study · NA · unknown
NCT04071652 — MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04073979 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mitralix
Last refreshed: 19 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04073979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing